INTRODUCTION
The ubiquitin-proteasome system (UPS) affects various intracellular processes and substrates. Ubiquitination is induced by covalent binding of ubiquitin to lysine residues of target proteins and needs to be catalyzed by an enzymatic cascade that includes E1 activating, E2 conjugating and E3 ligase enzymes (1) (2) (3) (4) . E1 (ubiquitin-activating enzymes) starts the ubiquitination process, and transfers ubiquitin to E2. E3 ubiquitin ligases are recruited by E2 conjugating enzymes and transfer ubiquitin from E2 to the target protein, resulting in the formation of polyubiquitin chains (5, 6 ). Proteins are monoubiquitylated by covalent attachment of one ubiquitin, but ubiquitin itself induces polyubiquitination of target proteins through isopeptide linkages. Many proteins are the targets of ubiquitinations, with many functions. Lysine 48 (K48)-linked ubiquitin chains are known primarily to induce proteasomal degradation of target proteins, whereas Lysine 63 (K63)-linked ubiquitin chains have multiple functions, such as DNA repair, cellular signaling, trafficking events and lysosomal degradation of target proteins (7-9) (Fig. 1) . Moreover, the UPS is involved in cancer development and therapy, because of their roles in cell cycle regulation, proliferation and apoptosis of cancer cells (10-12).
Ubiquitination is reversed by activation of deubiquitinases (DUBs) that depolymerize ubiquitin in polyubiquitin chains and cleave isopeptide bonds between ubiquitin and the target protein (13, 14) (Fig. 1 ). In mammals, there are approximately 100 DUBs, and they are classified into six classes depending on the catalytic domain; five cysteine proteases and one metalloprotease. Cysteine proteases include ubiquitin specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado-joseph disease proteases (MJDs) and MIU-containing novel DUB family (MINDY) protease (15-18). Metalloproteases include Jab1/MPN/MOV34 metalloenzymes (JAMMs). The ubiquitin E3 ligases and DUBs regulate protein stability and are strategic targets for drug discovery (19-21). Therefore, the modulation of protein expression through ubiquitination by E3 ubiquitin ligases and DUBs may enhance the efficiency of cancer therapies.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), one of the TNF ligand family members, selectively induces apoptosis in tumor cells, but not normal cells (22) (23) (24) . TRAIL can interact with the complex receptor of death receptors (DR) and decoy receptors (DcR), such as DR4, DR5, DcR1, DcR2, and osteoprotegrin (24). The two DRs initiate apoptosis signaling by binding TRAIL, whereas the Fig. 1 . The process of the ubiquitin proteasome system (UPS). 1) Ubiquitin (Ub) is activated by E1 activating enzymes in an ATP-dependent manner, then transferred to E2 conjugating enzymes. E2 conjugating enzymes can recruit E3 ligases enzymes with target substrates. E3 ligase enzymes directly catalyze transfer of activated ubiquitin from E2 conjugating enzymes to substrates, leading to the formation of polyubiquitin chains on target substrates. This process is called ubiquitination. Lys48-and Lys11-linked polyubiquitin chains usually induce degradation of target substrate through proteasome activation. Conversely, Lys63-linked polyubiquitin chains regulate cellular signaling and trafficking. 2) Ubiquitination of target substrate is reversed by deubiquitinases (DUBs). DUBs are critical roles for regulating the function of ubiquitinated proteins by removal of polyubiquitin chains. This process is called deubiquitination. In addition, ubiquitin released from substrates by DUBs can be recycled for activation of ubiquitination.
three DcRs inhibit TRAIL-mediated apoptosis by competing with the DRs (25, 26). TRAIL-mediated signaling is classified into extrinsic and intrinsic pathways, and results in activation of effector-caspases and induction of apoptosis (27). The extrinsic pathway is initiated by binding of TRAIL to DRs, which induces recruitment of FAS-associated protein with death domain (FADD) and pro-caspase-8, leading to death-inducing signal complex (DISC) formation. Activated caspase-8 by DISC formation directly activates caspase-3 and caspase-7, and eventually induces apoptosis (28). In the intrinsic pathway, truncation of Bid through activated caspase-8 is translocated to the mitochondria, causing cytochrome c release from mitochondria into the cytosol through mitochondria membrane permeabilization, which results in induction of apoptosis via activation of caspase-9 (29). However, many cancer cells exhibit down-regulation of DRs and acquire TRAIL resistance (30-32).
In this article, we review the modulatory mechanisms of the TRAIL-mediated extrinsic pathway through ubiquitination by E3 ubiquitin ligases and DUBs.
REGULATION OF DEATH RECEPTORS BY E3 LIGASE AND DUB
Various E3 ubiquitin ligases and DUBs are involved in the regulation of DR expressions. The E3 ligase c-Casitas B-lineage lymphoma (c-Cbl) directly binds to DRs, following induction of mono-ubiquitination of DRs. Interestingly, mono-ubiquitination of DR4/5 by c-Cbl is degraded in a lysosome-dependent manner, resulting in the increase of early phase TRAIL resistance (33). Moreover, knockdown of c-Cbl by small hairpin RNA (shRNA)-expressing adenovirus has been shown to enhance sensitivity to TRAIL-induced apoptosis in vivo and in vitro through the induction of DR4/5 expression (34).
Van de Kooij et al. reported that membrane associated RING-CH (MARCH)-8 induced down-regulation of DR4 expression on the cell surface, but not DR5 expression (35). MARCH-8 increased polyubiquitination of DR4 on a lysine residue 273 in the C-terminus, followed by degradation of DR4 protein through the lysosomal pathway. The authors reported that overexpression of MARCH-8 reduced sensitivity to TRAIL-mediated apoptosis, and the RING mutant form of MARCH-8 had no effect on resistance to TRAIL-induced apoptosis (35). Furthermore, lysosome inhibitor (bafilomycin A1) reversed DR4 degradation, whereas proteasome inhibitor (MG132) failed to recover DR4 expression. Therefore, the authors suggested that DR4 is degraded by lysosomes at steady-state. In addition, a previous study reported that proteasome or lysosomal inhibitors sensitized TRAIL-induced apoptosis through E3 ligase-mediated up-regulation of DR, overcoming TRAIL resistance in cancer cells (36) . Unlike the function of E3 ligase in DR regulation, the modulatory mechanisms of DR expression by DUB are largely unclear.
b-AP15 is a novel inhibitor of proteasome-associated DUBs (USP14 and UCHL5) in 19S proteasome regulatory particles, and both DUBs mediate removal of ubiquitin from the distal http://bmbreports.org BMB Reports end of polyubiquitinated proteins. Therefore, b-AP15 induces accumulation of highly polyubiquitinated proteins through inhibition of proteasome function (37, 38). DR5 is one of the proteins accumulated by b-AP15, and stabilization of DR5 by inhibition of proteasome activity increases TRAIL sensitivity (39). In addition, Oh et al. reported that monocyte chemotactic protein-induced protein-1 (MCPIP1) directly induced deubiquitination of DR5 through its DUB function (40). Ectopic expression of MCPIP1 induced degradation of DR5 in a lysosome-dependent manner, and b-AP15 reversed MCPIP1-mediated DR5 degradation (40). Taken together, the regulation of E3 ligases and DUBs is associated with upregulation of DR expressions, resulting in an increased sensitivity to TRAIL.
REGULATION OF CASPASE-8 BY E3 LIGASE AND DUB
When TRAIL binds DRs, DISC is formed by recruitment of pro-caspase-8 and FADD, following the activation of effect caspases, such as caspase-3 and -7 (28). Several studies have reported that ubiquitination is involved in activation and stabilization of caspase-8. Jin et al. reported that stimulation with TRAIL induced ubiquitination of caspase-8, and cullin3-based E3 ligase (CUL3) was associated with this ubiquitination (41). Neddylation of CUL3 by TRAIL treatment is augmented by cullin-RING ubiquitin ligases (42, 43), and interacts with pro-caspase-8 at DISC. CUL3 promotes K48-and K63-linked polyubiquitination of caspase-8 and polyubiquitinated caspase-8 translocates from the DISC to the ubiquitin-rich foci in a p62-dependent manner. Localization of caspase-8 with p62 in ubiquitin-rich foci drives full activation via autocatalytic processes of caspase-8, followed by induction of apoptosis (41). Moreover, knockdown of CUL3 inhibits caspase-8 polyubiquitination and activation, resulting in reduction of TRAIL-induced apoptosis (41). In contrast, these results were reversed by activation of A20 as a DUB, which removes the ubiquitin chains from pro-capsase-8 (41). Therefore, this evidence suggests that ubiquitin-mediated regulation of caspase-8 activity needs a balance between E3 ligase and DUB. The E3 ligase TNF receptor-associated factor 2 (TRAF2) directly interacts with caspase-8 at DISC and induces K48-linked polyubiquitination of caspase-8, leading to proteasomal degradation of activated caspase-8, and depletion of TRAF2 overcomes resistance to TRAIL through prevention of K48-linked polyubiquitination of caspase-8 (44, 45). CUL3-induced caspase-8 ubiquitination is on K461 in the p10 region of caspase-8 (41), whereas TRAF2-mediated ubiquitination sites are K224, 229, and 231 of the p10 region of caspase-8 (44). Whereas CUL3 and TRAF2 promote K48-linked polyubiquitination of caspase-8, another E3 ligase (HECTD3) increases ubiquitination of caspase-8 through K63-linked polyubiquitin chain (46). Caspase-8 ubiquitination by the induction of HECTD3 is associated with inactivation of caspase-8, but not degradation. Moreover, HECTD3 is overexpressed in breast carcinoma and inhibits TRAIL-induced caspase-8 cleavage in an E3 ligase activity-dependent manner (46). In addition, several other E3 ligases, WWP1, Siah2, and POSH, do not regulate ubiquitination of caspase-8. However, inhibition of WWP1 increases recruitment of caspase-8 into DISC, and silencing of Siah2 and POSH enhances caspase-8 activity, ultimately sensitizing TRAIL-mediated apoptosis (47, 48). Taken together, the various E3 ligases can regulate caspase-8 activity through ubiquitination of caspase-8, and determine sensitivity to TRAIL in cancer. But caspase-8 degradation and TRAIL sensitivity may depend on action of E3 ligases. Therefore, it remains to be identified how modifications of caspase-8 by E3 ligases differ from other molecular mechanisms, in order to promote cancer cell death.
REGULATION OF FADD BY E3 LIGASE AND DUB
Upon TRAIL stimulation, FADD binds to the death domain of DRs and recruits components of DISC, including caspase-8 and receptor-interacting protein kinase 1 (RIPK1) (28, 49, 50). Lee et al. reported that E3 ligase makorin ring finger protein 1 (MKRN1) down-regulated FADD protein levels through proteasomal degradation (51). MKRN1 directly interacts with FADD, and exogenous MKRN1 induces FADD ubiquitination and destabilization. Depletion of MKRN1 rapidly promotes DISC formation and caspase-8 activation, ultimately increasing TRAIL-induced cell death in vitro and in vivo (51). In addition, knockdown of MKRN1 facilitates necroptosis through increase of necrosome formation upon caspase-8 inhibition. However, DUB-mediated FADD regulation is still unknown.
REGULATION OF RIPK1 BY E3 LIGASE AND DUB
RIPK1 is involved in both complex I and complex II TRAIL signaling through FADD-caspase-8-dependent recruitment to DISC. The C-terminal death domain (DD) of RIPK1 can interact with other DD-containing proteins (52, 53). Therefore, RIPK1 has emerged as a central controller, downstream of DR signaling, that determines cell fate (54, 55). Interestingly, A20 has two domains that are an N-terminal OTU domain of DUB and a C-terminal Zinc finger domain of E3 ligase (56). Several reports have suggested that the function of A20 as an E3 ligase is to inhibit TRAIL-induced apoptosis through ubiquitination of RIPK1 (57, 58). A20 increases K63-linked polyubiquitin chainmediated RIPK1 ubiquitination, and ubiquitination of RIPK1 by A20 binds to caspase-8 protease domains, followed by protection against TRAIL-induced apoptosis via inhibition of capsase-8 dimerization (57). In addition, silencing of A20 expression increases RIPK1 cleavage-dependent TRAIL sensitivity (58). Therefore, A20 has a dual function as both E3 ligase and DUB, and differentially regulated according to substrate target.
Recently, Lafont et al. reported that RIPK1 was a substrate of the linear ubiquitin chain assembly complex (LUBAC), upon http://bmbreports.org 
REGULATION OF c-FLIP BY E3 LIGASE AND DUB
The long and short isoforms of cellular FLICE-inhibitory protein (c-FLIP) are major inhibitors of TRAIL-mediated apoptosis, and interfere with caspase-8-mediated DISC formation through competition with caspase-8 (24, 61, 62). TRAIL-induced apoptosis in vitro and in a xenograft model (76) . Although E3 ligase-dependent degradation and stabilization of c-FLIP has been demonstrated, studies on the DUBdependent regulation of c-FLIP are lacking. Therefore, further study is needed to identify the correct mechanism of direct c-FLIP regulation through DUBs. We summarized the molecular mechanisms of E3 ligases and DUBs that regulate expression and activation of extrinsic pathway-related proteins ( Fig. 2 and Table 1 ).
Many cancer cells have high levels of c-FLIP expression (63-65), and overexpression of c-FLIP is associated with resistance to TRAIL-mediated apoptosis and correlation with a poor prognosis (66-68). Several studies reported E3 ligase Itch regulates proteasomal degradation of c-FLIP(L) through its K48-linked ubiquitination (69, 70). Itch interacts with c-FLIP(L) and induces its degradation, but Itch does not interact with c-FLIP(S) (69). Down-regulation of c-FLIP(L) by

-FLIP(S) steady state levels and induces down-regulation of c-FLIP(S) through Itch-mediated c-FLIP(S) ubiquitination, followed by induction of TRAIL sensitivity (75). Recently, Jeong et al. demonstrated that USP8 directly interacted with the caspase-like domain in c-FLIP(L) and induced deubiquitination and stabilization of c-FLIP(L), but not c-FLIP(S). Depletion of USP8 destabilized c-FLIP(L) through
CONCLUSION
Because cancer cells preferentially have TRAIL receptor expression on their cell surface, DRs-mediated TRAIL signaling can provide a therapeutic target for cancer treatment. Therefore, various ways to improve TRAIL-mediated apoptosis signals through DRs regulation have been investigated. The UPS is a key modulator of cellular physiological processes in cancer, such as cell cycle, proliferation and apoptosis. In addition, the controlled activation and degradation of TRAIL signaling regulators by ubiquitination affect TRAIL-induced apoptosis in many cancer cells. Many studies have demonstrated that UPS-mediated regulation of DRs, as well as DISC components, modulates sensitivity and resistance to TRAIL-mediated apoptosis. Here, we describe the regulatory molecular mechanisms of the TRAIL extrinsic pathway through E3 ligases and DUBs (Fig. 2) . Since TRAIL treatment alone is inefficient in treating cancer and preventing its recurrence, targeting E3 ligases and DUBs for regulation of TRAIL signaling could provide management for development of new TRAIL adjuvants. 
